|Table of Contents|

Detection and clinical significance of PD-1/CD28 on the surface of peripheral blood T lymphocytes in patients with lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 05
Page:
772-776
Research Field:
Publishing date:

Info

Title:
Detection and clinical significance of PD-1/CD28 on the surface of peripheral blood T lymphocytes in patients with lung cancer
Author(s):
HEI Ruoxuan1; LI Simin1; LIU Li1; DONG Ke1; CHEN Yanwei2; GAO Zhaowei1
1.Department of Clinical Laboratory;2.Department of Respiratory Medicine,Tangdu Hospital of the Air Force Medical University,Shaanxi Xi'an 710038,China.
Keywords:
lung cancer; T lymphocytes; PD-1; CD28
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2025.05.008
Abstract:
Objective:To investigate the alterations in the expression levels of PD-1 and CD28 on the surface of T lymphocytes present in the peripheral blood of lung cancer patients.Methods:A total of 662 lung cancer patients who visited our hospital from January 2024 to December 2024 were included in this study,comprising 556 patients with non-metastatic lung cancer and 66 patients with metastatic lung cancer.Additionally,a control group was established consisting of 39 healthy individuals examined during the same period.Flow cytometry was employed to assess both the quantity and proportion of PD-1/CD28 positive T lymphocytes within the peripheral blood samples.Results:Compared to the healthy control group,lung cancer patients exhibited a significant decrease in both the number of T lymphocytes (CD45+CD3+) and helper T lymphocytes (CD45+CD3+CD4+) (P＜0.05).Furthermore,when comparing the lung cancer metastasis group to the non-metastasis group,there was also a notable reduction in the number of T lymphocytes and helper T lymphocytes (P＜0.05).In addition,relative to the healthy control group,lung cancer patients demonstrated a significant increase in the ratio of CD3+PD-1+ T lymphocytes (P＜0.05); however,no significant difference was observed between the metastasis and non-metastasis groups regarding this ratio (P=0.303).The ratio and quantity of CD3+CD4+PD-1+ T lymphocytes were significantly higher in the lung cancer non-metastasis group compared to those in the healthy control group (P＜0.05),while an increased ratio of CD3+CD4+PD-1+ T cells was noted within the lung cancer metastasis group as well (P＜0.05).Moreover,when contrasting with both healthy controls and individuals from the lung cancer non-metastasis cohort,there was a marked increase in the ratio of CD3+CD8+PD-1+ T lymphocytes within the lung cancer metastasis group (P＜0.05).Lastly,compared to healthy controls,there was a significant reduction in numbers of CD3+CD28+,CD3+CD4+CD28+,and CD3+CD8+CD28+T lymphocytes among lung cancer patients (P＜0.05).Conclusion:The proportion of PD-1+ T lymphocytes in the peripheral blood of lung cancer patients is elevated,whereas the number of CD28+ T lymphocytes is decreased.This suggests that the T cell immune function in lung cancer patients is compromised,which may be closely associated with the onset and progression of lung cancer.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA:A Cancer Journal for Clinicians,2024,74(3):229-263.
[2] PARDOLL D.The blockade of immune checkpoints in cancer immunotherapy ［J］.Nature Reviews Cancer,2012,12(4):252-264.
[3] BEWERSDORF JP,SHALLIS RM,ZEIDAN AM.Immune checkpoint inhibition in myeloid malignancies:Moving beyond the PD-1/PD-L1 and CTLA-4 pathways ［J］.Blood Reviews,2021,45:100709.
[4] TOPALIAN SL,TAUBE JM,PARDOLL DM.Neoadjuvant checkpoint blockade for cancer immunotherapy ［J］.Science,2020,367(6477):eaax0182.
[5] ESENSTEN JH,HELOU YA,CHOPRA G,et al.CD28 costimulation:From mechanism to therapy ［J］.Immunity,2016,44(5):973-988.
[6] MAHONEY KM,RENNERT PD,FREEMAN GJ.Combination cancer immunotherapy and new immunomodulatory targets ［J］.Nature Reviews Drug Discovery,2015,14(8):561-584.
[7] HUANG Y,ZHU M,JI M,et al.Air pollution,genetic factors,and the risk of lung cancer:A prospective study in the UK biobank ［J］.American Journal of Respiratory and Critical Care Medicine,2021,204(7):817-825.
[8] SASCO AJ,SECRETAN MB,STRAIF K.Tobacco smoking and cancer:a brief review of recent epidemiological evidence ［J］.Lung Cancer,2004,45 Suppl 2:S3-S9.
[9] 杜洋，范承娟，申维喜，等.非小细胞肺癌免疫治疗研究进展［J］.现代肿瘤医学，2021,29（13）：2368-2371. DU Y,FAN CJ,SHEN WX，et al.Progress in immunotherapy of non-small cell lung cancer［J］.Modern Oncology,2021,29（13）：2368-2371.
[10] 孙佳琦,黄俊星.PD-1/PD-L1抑制剂及其生物标志物在食管鳞状细胞癌治疗中的研究进展［J］.癌症进展,2019,17(16):1871-1874. SUN JQ,HUANG JX.Research progress on PD-1/PD-L1 inhibitors and their biomarkers in the treatment of esophageal squamous cell carcinoma ［J］.Cancer Progress,2019,17(16):1871-1874.
[11] YIN J,WU Y,YANG X,et al.Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer:Occurrence and mechanism ［J］.Frontiers in Immunology,2022,13(7):830631.
[12] RECK M,RODRGUEZ-ABREU D,ROBINSON AG,et al.Updated analysis of KEYNOTE-024:Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater ［J］.Journal of Clinical Oncology,2019,37(7):537-546.
[13] YANG Z,LIU X,ZHU J,et al.Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1 ［J］.Cancer Cell,2025,43(1):86-102.e10.
[14] KAMPHORST AO,WIELAND A,NASTI T,et al.Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent ［J］.Science,2017,355(6332):1423-1427.
[15] PIETROBON V,TODD LA,GOSWAMI A,et al.Improving CAR T-cell persistence ［J］.International Journal of Molecular Sciences,2021,22(19):10828.
[16] KHOPANLERT W,CHOOCHUEN P,MANEECHAI K,et al.Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness ［J］.Molecular Therapy-Oncolytics,2024,32(3):200837.
[17] LIU C,HU Q,HU K,et al.Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer ［J］.Journal of Translational Medicine,2019,17(1):120.
[18] 马群.T淋巴细胞表面因子PD-1和PDL1在非小细胞肺癌患者外周血中表达特点研究［D］.新乡：新乡医学院,2022. MA Q.Study on the expression characteristics of surface factors PD-1 and PDL1 of T lymphocytes in peripheral blood of patients with non-small cell lung cancer ［D］.Xinxiang:Xinxiang Medical University,2022.
[19] 吉顺荣,姚宛彤,张波,等.胰腺癌患者外周血CD8+CD28+和CD8+CD28-T淋巴细胞亚群的分析［J］.上海医学,2012,35(04):316-319. JI SR,YAO WT,ZHANG B,et al.Analysis of CD8+CD28+ and CD8+CD28- T lymphocyte subsets in peripheral blood of patients with pancreatic cancer ［J］.Shanghai Medical Journal,2012,35(04):316-319.
[20] 张晓倩,李金星,高伟,等.肺癌患者外周血CD8+CD28+、CD4+CD25+调节性T淋巴细胞水平变化及意义［J］.山东医药,2012,52(34):42-44. ZHANG XQ,LI JX,GAO W,et al.Changes and significance of CD8+CD28+ and CD4+CD25+ regulatory T lymphocytes in peripheral blood of patients with lung cancer ［J］.Shandong Medical Journal,2012,52(34):42-44.

Memo

Memo:
National Natural Science Foundation of China(No.82070096）；国家自然科学基金面上项目（编号：82070096）
Last Update: 1900-01-01